AWhat changed
Showed selective inhibition of Bcr-Abl-positive cells, tumors and CML colony formation.
Scientific scope
The record is the exact eight-author 1996 Nature Medicine paper. It is preclinical and ex vivo evidence, not the later STI571 phase-1 trial, randomized comparison, durable-outcome evidence or proof that every BCR–ABL-positive disease responds.
Evidence
The linked sources identify this contribution and its scope. WRS has not independently reconstructed the scientific claims. The record is the exact eight-author 1996 Nature Medicine paper. It is preclinical and ex vivo evidence, not the later STI571 phase-1 trial, randomized comparison, durable-outcome evidence or proof that every BCR–ABL-positive disease responds.
Contributors
- Brian J. Druker · SCIENCE: Named source author of the scoped work; individual effort shares are not measured.
- Shu Tamura · SCIENCE: Named source author of the scoped work; individual effort shares are not measured.
- Elisabeth Buchdunger · SCIENCE: Named source author of the scoped work; individual effort shares are not measured.
- Sayuri Ohno · SCIENCE: Named source author of the scoped work; individual effort shares are not measured.
- Gerald M. Segal · SCIENCE: Named source author of the scoped work; individual effort shares are not measured.
- Shane Fanning · SCIENCE: Named source author of the scoped work; individual effort shares are not measured.
- Jürg Zimmermann · SCIENCE: Named source author of the scoped work; individual effort shares are not measured.
- Nicholas B. Lydon · SCIENCE: Named source author of the scoped work; individual effort shares are not measured.
Provisional WRS assessment, edition 2026-10-16.1. Independent expert calibration is pending. This grade does not certify correctness or assign ownership.
Full scientific record · Browse contribution grades · Request a correction